Application No. 10/561,756 2 Docket No.: H0664.70032US00 Amendment dated August 2, 2011

After Final Office Action of May 5, 2011

AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1-13. (Canceled)

14. (Currently amended) A method for treating a mood disorder depression in a human patient, which comprises administering to a patient in need thereof a therapeutically effective amount of cannabichromene (CBC)

wherein the CBC is substantially pure or is an extract from a cannabis plant that contains greater than or equal to 30% CBC of the total cannabinoid content, and wherein the CBC is administered as a unit dosage form that comprises CBC in an amount of 0.1 mg to 1000 mg

wherein the mood disorder is morbid or clinical depression, unipolar mood disorder, bipolar mood disorder, syndromal depression, panie disorder or anxiety.

15.-17. (Canceled)

- 18. (Previously presented) The method according to claim 14 wherein the CBC is present in an extract of at least one cannabis plant.
- 19. (Previously presented) The method according to claim 14, wherein the CBC is administered nasally, sublingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intramuscularly, subcutaneously, transdermally, intra-vaginally, intra-urethrally, by nebuliser, as inhaled vapour or by installation directly into the bladder.

20.-24. (Canceled)

25. (Previously presented) The method according to claim 18, wherein the extract comprises substantially all the naturally occurring cannabinoids in said at least one cannabis plant.

Application No. 10/561,756 3 Docket No.: H0664.70032US00 Amendment dated August 2, 2011

After Final Office Action of May 5, 2011

 (Previously presented) The method according to claim 18, wherein the extract is enriched for CBC.

27. (Previously presented) The method according to claim 14, wherein the CBC is administered in an isolated and substantially pure form.

28. (Previously presented) The method according to claim 14, wherein the CBC is administered together with one or more pharmaceutically acceptable diluents, excipients or carriers.

 (New) The method according to claim 14, wherein the CBC is not administered as inhaled vapour.